EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
Public ClinicalTrials.gov record NCT04669002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination should improve therapeutic responses in the recurrent ovarian cancer disease setting. EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and as a result create preferential accumulation of EP0057, and therefore of the payload Camptothecin, to translate into maximum tumour cell killing.
Study identification
- NCT ID
- NCT04669002
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2020 (Actual)
- Primary completion
- Feb 17, 2023 (Actual)
- Completion
- May 5, 2023 (Actual)
- Last update posted
- Aug 2, 2023
2020 – 2023
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine | Irvine | California | 92687 | — |
| Florida Cancer Specialists and Research Institute | Lady Lake | Florida | 32159 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| North Shore Hematology Oncology Associates PC DBA New York Cancer and Blood Specialists | East Setauket | New York | 11733 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| Magee Women's Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29606 | — |
| Sarah Cannon | Nashville | Tennessee | 37203 | — |
| Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04669002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04669002 live on ClinicalTrials.gov.